Naringin dihydrochalcone

CAS No. 18916-17-1

Naringin dihydrochalcone ( Naringin DC )

Catalog No. M18164 CAS No. 18916-17-1

Naringin Dihydrochalcone(Naringin DC) is an inhibitor of CYP enzymes, used as an artificial sweetener.

Purity : 98%

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
500MG 38 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Naringin dihydrochalcone
  • Note
    Research use only, not for human use.
  • Brief Description
    Naringin Dihydrochalcone(Naringin DC) is an inhibitor of CYP enzymes, used as an artificial sweetener.
  • Description
    Naringin Dihydrochalcone(Naringin DC) is an inhibitor of CYP enzymes, used as an artificial sweetener.
  • Synonyms
    Naringin DC
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    Others-Field
  • Indication
    ——

Chemical Information

  • CAS Number
    18916-17-1
  • Formula Weight
    582.55
  • Molecular Formula
    C27H34O14
  • Purity
    98%
  • Solubility
    DMSO : ≥ 32 mg/mL; 54.93 mM
  • SMILES
    C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1Oc1cc(c(c(c1)O)C(=O)CCc1ccc(cc1)O)O)CO)O)O)O)O)O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Shin W, et al. J Med Chem, 1995, 38(21), 4325-4331.
molnova catalog
related products
  • MAGE-A3 195-203

    This peptide MAGE-3-encoded HLA-A24 epitope is a high MHC binder.The identification of this MAGE-3/HLA-A24 peptide may as a result effectiveially offer the opportunities to design peptide-based immunotherapeutic approaches that might prove to be potent in treating patients with MAGE-3-positive malignant tumors.

  • Curcumenol

    Curcumenol, one of the major components of Zedoary turmeric oil, is an antibiotic drug which has anti-Y, anti-inflammation activity.

  • Naringenin triacetat...

    Naringenin triacetate exhibits a better binding affinity with multiple crystal structures of first bromodomain BRD4 (BRD4 BD1) when compared with the known inhibitors.